Table 3.
Baseline characteristics and outcomes of selected series of NMAT for lymphoma/CLL
| Reference | n | Age, y (median) | Histology (no.) | Regimen | Chemosensitive, % | CR at transplantation, % | Prior treatment, no. | Bulk > 5 cm, % | HSCT-CI ≥ 3, % | OS, % (y) | PFS, % (y) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | 47 | 53 | FL | FCR | 100 | 38 | 3 | NR | NR | 85 (5) | 83 (5) |
| 6 | 35 | 58 | MCL | PFA/FCR | 83 | 46 | 3 | NR | 40 | 53 (6) | 46 (6) |
| 26 | 41 | 54 | CLL | FluMel-Campath | 83 | 12 | 3 | NR | NR | 51 (2) | 45 (2) |
| 2 | 82 | 56 | CLL/SLL | 2 Gy TBI ± Flu | 51 | 6 | 3 | 29* | 28 | 50 (5) | 39 (5) |
| 3 | 31 | 52 | DLBCL | 2 Gy TBI ± Flu | 72 | 44 | 4 | NR | 41 | 45 (3) | 35 (3) |
| 4 | 62 | 54 | Indolent (87% FL) | 2 Gy TBI ± Flu | 63 | 26 | 6 | 8 | 27 | 52 (3) | 43 (3) |
| 1 | 33 | 54 | MCL | 2 Gy TBI + Flu | 61 | 39 | 4 | 18* | 9† | 65 (2) | 60 (2) |
| 24 | 40 | 55 | Indolent (32), MCL (8) | Zevalin + Flu + 2 Gy TBI | 85 | 18 | 4 | 18 | NR | 51 (2) | 43 (2) |
| Current study | 40 | 58 | Indolent (18), DLBCL (14), MCL (8) | Zevalin + Flu + 2 Gy TBI | 15 | 0 | 6 | 43 | 63 | 54 (2) | 31 (2) |
HSCT-CI indicates Hematopoietic Stem Cell Transplant Comorbidity Index22; PFA, cisplatin, fludarabine, and cytarabine; Flu, fludarabine; Mel, melphalan; and NR, not reported.
*
≥ 5 cm.
†
Charlson comorbidity scores.27